The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study

Endocrine

Volumn 49, Issue 1, 2015, Pages 242-249

  Krysiak, Robert ^a   Okrzesik, Joanna ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bromocriptine; Hyperprolactinaemia; Insulin resistance; Metformin

Indexed keywords

ANTIDIABETIC AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; METFORMIN; PROLACTIN;

ADULT; BLOOD; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERPROLACTINEMIA; PILOT STUDY;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERPROLACTINEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; PILOT PROJECTS; PROLACTIN;

EID: 84938571733     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0428-2     Document Type: Article

References (44)

1. D. Yavuz, O. Deyneli, I. Akpinar, E. Yildiz, H. Gözü, O. Sezgin et al., Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinaemic pre-menopausal women. Eur. J. Endocrinol. 149, 187–193 (2003)
2. C.M. dos Santos Silva, F.R. Barbosa, L. Warszawski, R. Fontes, R.C. Domingues, M.R. Gadelha, BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 19, 800–805 (2011)
3. O. Serri, L. Li, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. (Oxf.) 64, 366–370 (2006)
4. K. Berinder, T. Nyström, C. Höybye, K. Hall, A.L. Hulting, Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14, 199–207 (2011)
5. X.B. Jiang, C.L. Li, D.S. He, Z.G. Mao, D.H. Liu, X. Fan et al., Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 17, 232–239 (2014)
6. X.B. Jiang, D.S. He, Z.G. Mao, X. Fan, N. Lei, B. Hu et al., BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biol. 34, 1171–1176 (2013)
7. R.A. DeFronzo, Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34, 789–794 (2011)
8. H. Pijl, S. Ohashi, M. Matsuda, Y. Miyazaki, A. Mahankali, V. Kumar et al., Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23, 1154–1161 (2000)
9. V. Kamath, C.N. Jones, J.C. Yip, B.B. Varasteh, A.H. Cincotta, G.M. Reaven et al., Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinaemic women. Diabetes Care 20, 1697–1701 (1997)
10. A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. (Oxf.) 79, 845–852 (2013)
11. R.S. Auriemma, L. Granieri, M. Galdiero, C. Simeoli, Y. Perone, P. Vitale et al., Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98, 299–310 (2013)
12. American Diabetes Association, Standards of medical care in diabetes - 2013. Diabetes Care 36(Suppl. 1), S11–S66 (2013)
13. J.H. Scarpello, H.C. Howlett, Metformin therapy and clinical uses. Diab. Vasc. Dis. Res. 5, 157–167 (2008)
14. C. Cappelli, M. Rotondi, I. Pirola, B. Agosti, E. Gandossi, U. Valentini et al., TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 32, 1589–1590 (2009)
15. R.A. Vigersky, A. Filmore-Nassar, A.R. Glass, Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab. 91, 225–227 (2006)
16. M.L. Isidro, M.A. Penín, R. Nemina, F. Cordido, Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 32, 79–82 (2007)
17. A. Oride, H. Kanasaki, I.N. Purwana, K. Miyazaki, Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs. Pituitary 13, 236–241 (2010)
18. A.D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, O. Gamba, Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 81, 114–119 (2004)
19. Z. Velija-Ašimi, Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn. J. Basic Med. Sci. 13, 180–185 (2013)
20. E. Billa, N. Kapolla, S.C. Nicopoulou, E. Koukkou, E. Venaki, S. Milingos et al., Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol. Endocrinol. 25, 427–434 (2009)
21. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, A.J. Duleba, Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J. Clin. Endocrinol. Metab. 94, 4938–4945 (2009)
22. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, A.J. Duleba, Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J. Clin. Endocrinol. Metab. 96, 3493–3501 (2011)
23. R. Krysiak, B. Okopien, Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin. Endocrinol. 75, 404–406 (2011)
24. A. Borai, C. Livingstone, G.A. Ferns, The biochemical assessment of insulin resistance. Ann. Clin. Biochem. 44(Pt 4), 324–342 (2007)
25. World Health Organization, Waist circumference and waist–hip ratio: report of a WHO Expert Consultation Geneva, 8–11 December 2008
26. G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm et al., 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013)
27. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002)
28. R.C. Turner, R.R. Holman, I.M. Stratton, UK Prospective Diabetes Study: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998)
29. R. Krysiak, B. Okopien, The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. Exp. Clin. Endocrinol. Diabetes (2014). doi:10.1055/s-0034-1382048
30. R. Krysiak, B. Okopien, Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin. Endocrinol. (Oxf.) 75, 404–406 (2011)
31. R. Krysiak, A. Gdula-Dymek, B. Okopien, Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol. Rep. 65, 429–434 (2013)
32. R. Krysiak, A. Gdula-Dymek, B. Okopien, Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol. Rep. 65, 1311–1316 (2013)
33. C.J. Glueck, N. Goldenberg, P. Wang, Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 22, 815–826 (2009)
34. G. Iván, N. Szigeti-Csúcs, M. Oláh, G.M. Nagy, M.I. Góth, Treatment of pituitary tumors: dopamine agonists. Endocrine 28, 101–110 (2005)
35. C.L. Li, C.Y. Pan, J.M. Lu, Y. Zhu, J.H. Wang, X.X. Deng et al., Effect of metformin on patients with impaired glucose tolerance. Diabet. Med. 16, 477–481 (1999)
36. M.S. Arslan, O. Topaloglu, M. Sahin, E. Tutal, A. Gungunes, E. Cakir et al., Preclinical atherosclerosis in patients with prolactinoma. Edocr. Pract. 20, 447–451 (2014)
37. S.M. Twigg, M.C. Kamp, T.M. Davis, E.K. Neylon, J.R. Flack, Australian Diabetes Society; Australian Diabetes Educators Association: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med. J. Aust. 186, 461–465 (2007)
38. A. Klibanski, Clinical practice. Prolactinomas. N. Engl. J. Med. 362, 1219–1226 (2010)
39. L. Vilar, M. Fleseriu, M.D. Bronstein, Challenges and pitfalls in the diagnosis of hyperprolactinaemia. Arq. Bras. Endocrinol. Metabol. 58, 9–22 (2014)
40. P. Iglesias, J.J. Díez, Macroprolactinoma: a diagnostic and therapeutic update. QJM 106, 495–504 (2013)
41. K. Labuzek, D. Suchy, B. Gabryel, A. Bielecka, S. Liber, B. Okopien, Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol. Rep. 62, 956–965 (2010)
42. A.J. Scheen, Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30, 359–371 (1996)
43. J.A. Clemens, C.J. Shaar, Control of prolactin secretion in mammals. Fed. Proc. 39, 2588–2592 (1980)
44. M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000)